Integra LifeSciences (IART) Misses Q3 EPS by 2c; offers guidance

Integra LifeSciences (NASDAQ: IART) reported Q3 EPS of $0.76, $0.02 worse than the analyst estimate of $0.78. Revenue for the quarter came in at $382.4 million versus the consensus estimate of $387.22 million.

GUIDANCE:

Integra LifeSciences sees FY2023 EPS of $3.10-$3.14, versus the consensus of $3.14. Integra LifeSciences sees FY2023 revenue of $1.541-1.547 million, versus the consensus of $1.555 million.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.

You May Also Be Interested In

• Integra LifeSciences Announces Key Executive Appointments
• GTA VI to catalyze a multi-year improvement in earnings power for TTWO, BTIG says
• TD Cowen cuts Flowserve to Hold, flags guidance reset risk amid Mideast woes